GlaxoSmithKline's corporate venturing team continues active deal rate with movement in its personnel.
At nearly the first anniversary of Christoph Westphal taking over the top job at SR One, the corporate venturing unit of UK-listed drugs company GlaxoSmithKline (GSK), has seen a number of personnel moves.
Michael Diem has become vice-president of business development at the rare diseases division of GSK after joining SR One in 2005.
His internal move follows the departure of two other SR One partners. Mathieu Lane has left to become a vice-president of investment banking at alternative investments…
